BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Lurbinectedin readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Lurbinectedin\, from ClinicalTrials.gov e
 stimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT05099666-2601@assetmemo.bio
DTSTAMP:20261121T005647Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Lurbinectedin: Phase 1/2 readout est. (NCT05099666)
DESCRIPTION:Lurbinectedin\, phase 1/2.\nStudy: Lurbinectedin + Doxorubicin 
 In Leiomyosarcoma\nEstimated primary completion: December 2026. This is a 
 ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can mo
 ve.\nDrug page: https://assetmemo.bio/drug/lurbinectedin#upcoming-events\n
 Registry record: https://clinicaltrials.gov/study/NCT05099666
URL:https://assetmemo.bio/drug/lurbinectedin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06497530-2601@assetmemo.bio
DTSTAMP:20261121T005647Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Lurbinectedin: Phase 2 readout est. (NCT06497530)
DESCRIPTION:Lurbinectedin\, phase 2\, Small Cell Lung Cancer.\nStudy: Maint
 enance Lurbinectedin in Combination With Serplulimab for Patients With ES-
 SCLC\nEstimated primary completion: December 2026. This is a ClinicalTrial
 s.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pag
 e: https://assetmemo.bio/drug/lurbinectedin#upcoming-events\nRegistry reco
 rd: https://clinicaltrials.gov/study/NCT06497530
URL:https://assetmemo.bio/drug/lurbinectedin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06501976-2601@assetmemo.bio
DTSTAMP:20261121T005647Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Lurbinectedin: Phase 2 readout est. (NCT06501976)
DESCRIPTION:Lurbinectedin\, phase 2\, Small Cell Lung Cancer.\nStudy: An Ex
 ploratory Study of Lurbinectedin With Radiotherapy in SCLC With Single-les
 ion Progression After First Course Treatment\nEstimated primary completion
 : December 2026. This is a ClinicalTrials.gov estimate\, not a confirmed r
 eadout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/lurb
 inectedin#upcoming-events\nRegistry record: https://clinicaltrials.gov/stu
 dy/NCT06501976
URL:https://assetmemo.bio/drug/lurbinectedin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05578326-2601@assetmemo.bio
DTSTAMP:20261121T005647Z
DTSTART;VALUE=DATE:20261225
DTEND;VALUE=DATE:20261226
SUMMARY:Lurbinectedin: Phase 2 readout est. (NCT05578326)
DESCRIPTION:Lurbinectedin\, phase 2\, Small Cell Lung Cancer.\nStudy: Study
  of Trilaciclib and Lurbinectidin\nEstimated primary completion: 25 Decemb
 er 2026. This is a ClinicalTrials.gov estimate\, not a confirmed readout d
 ate\, and it can move.\nDrug page: https://assetmemo.bio/drug/lurbinectedi
 n#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT05
 578326
URL:https://assetmemo.bio/drug/lurbinectedin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05636111-2601@assetmemo.bio
DTSTAMP:20261121T005647Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Lurbinectedin: Phase 1 readout est. (NCT05636111)
DESCRIPTION:Lurbinectedin\, phase 1.\nStudy: Phase 1b of Lurbinectedin in C
 ombination With Weekly Paclitaxel and Bevacizumab in Platinum-resistant Ov
 arian Cancer\nEstimated primary completion: 31 December 2026. This is a Cl
 inicalTrials.gov estimate\, not a confirmed readout date\, and it can move
 .\nDrug page: https://assetmemo.bio/drug/lurbinectedin#upcoming-events\nRe
 gistry record: https://clinicaltrials.gov/study/NCT05636111
URL:https://assetmemo.bio/drug/lurbinectedin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07121478-2601@assetmemo.bio
DTSTAMP:20261121T005647Z
DTSTART;VALUE=DATE:20270301
DTEND;VALUE=DATE:20270302
SUMMARY:Lurbinectedin: Phase 2 readout est. (NCT07121478)
DESCRIPTION:Lurbinectedin\, phase 2.\nStudy: Patients With High-grade Pancr
 eatic Neuroendocrine Tumors\nEstimated primary completion: 1 March 2027. T
 his is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and 
 it can move.\nDrug page: https://assetmemo.bio/drug/lurbinectedin#upcoming
 -events\nRegistry record: https://clinicaltrials.gov/study/NCT07121478
URL:https://assetmemo.bio/drug/lurbinectedin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07640932-2601@assetmemo.bio
DTSTAMP:20261121T005647Z
DTSTART;VALUE=DATE:20270430
DTEND;VALUE=DATE:20270501
SUMMARY:Lurbinectedin: Phase 2 readout est. (NCT07640932)
DESCRIPTION:Lurbinectedin\, phase 2\, Small Cell Lung Cancer.\nStudy: Lurbi
 nectedin Plus Paclitaxel Versus Paclitaxel in Patients With Previously Tre
 ated Small Cell Lung Cancer\nEstimated primary completion: April 2027. Thi
 s is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it
  can move.\nDrug page: https://assetmemo.bio/drug/lurbinectedin#upcoming-e
 vents\nRegistry record: https://clinicaltrials.gov/study/NCT07640932
URL:https://assetmemo.bio/drug/lurbinectedin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06228066-2601@assetmemo.bio
DTSTAMP:20261121T005647Z
DTSTART;VALUE=DATE:20270901
DTEND;VALUE=DATE:20270902
SUMMARY:Lurbinectedin: Phase 2 readout est. (NCT06228066)
DESCRIPTION:Lurbinectedin\, phase 2.\nStudy: Lurbinectedin With or Without 
 Avelumab in Small Cell Carcinoma of the Bladder (LASER)\nEstimated primary
  completion: 1 September 2027. This is a ClinicalTrials.gov estimate\, not
  a confirmed readout date\, and it can move.\nDrug page: https://assetmemo
 .bio/drug/lurbinectedin#upcoming-events\nRegistry record: https://clinical
 trials.gov/study/NCT06228066
URL:https://assetmemo.bio/drug/lurbinectedin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05652686-2601@assetmemo.bio
DTSTAMP:20261121T005647Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Lurbinectedin: Phase 1/2 readout est. (NCT05652686)
DESCRIPTION:Lurbinectedin\, phase 1/2\, Small Cell Lung Cancer.\nStudy: A S
 tudy of Peluntamig (PT217) in Patients With Neuroendocrine Carcinomas Expr
 essing DLL3 (the SKYBRIDGE Study)\nEstimated primary completion: December 
 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout date
 \, and it can move.\nDrug page: https://assetmemo.bio/drug/lurbinectedin#u
 pcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT05652
 686
URL:https://assetmemo.bio/drug/lurbinectedin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06496048-2601@assetmemo.bio
DTSTAMP:20261121T005647Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Lurbinectedin: Phase 3 readout est. (NCT06496048)
DESCRIPTION:Lurbinectedin\, phase 3\, Small Cell Lung Cancer.\nStudy: Lurbi
 nectedin or in Combination with Irinotecan Versus Topotecan in Patients wi
 th Relapsed SCLC\nEstimated primary completion: 31 December 2027. This is 
 a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can 
 move.\nDrug page: https://assetmemo.bio/drug/lurbinectedin#upcoming-events
 \nRegistry record: https://clinicaltrials.gov/study/NCT06496048
URL:https://assetmemo.bio/drug/lurbinectedin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05734066-2601@assetmemo.bio
DTSTAMP:20261121T005647Z
DTSTART;VALUE=DATE:20280128
DTEND;VALUE=DATE:20280129
SUMMARY:Lurbinectedin: Phase 1/2 readout est. (NCT05734066)
DESCRIPTION:Lurbinectedin\, phase 1/2.\nStudy: Study of Lurbinectedin Monot
 herapy in Pediatric and Young Adult Participants With Relapsed/Refractory 
 Ewing Sarcoma\nEstimated primary completion: 28 January 2028. This is a Cl
 inicalTrials.gov estimate\, not a confirmed readout date\, and it can move
 .\nDrug page: https://assetmemo.bio/drug/lurbinectedin#upcoming-events\nRe
 gistry record: https://clinicaltrials.gov/study/NCT05734066
URL:https://assetmemo.bio/drug/lurbinectedin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05918640-2601@assetmemo.bio
DTSTAMP:20261121T005647Z
DTSTART;VALUE=DATE:20280730
DTEND;VALUE=DATE:20280731
SUMMARY:Lurbinectedin: Phase 1/2 readout est. (NCT05918640)
DESCRIPTION:Lurbinectedin\, phase 1/2.\nStudy: Lurbinectedin in FET-Fused T
 umors\nEstimated primary completion: 30 July 2028. This is a ClinicalTrial
 s.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pag
 e: https://assetmemo.bio/drug/lurbinectedin#upcoming-events\nRegistry reco
 rd: https://clinicaltrials.gov/study/NCT05918640
URL:https://assetmemo.bio/drug/lurbinectedin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05800587-2601@assetmemo.bio
DTSTAMP:20261121T005647Z
DTSTART;VALUE=DATE:20280801
DTEND;VALUE=DATE:20280802
SUMMARY:Lurbinectedin: Phase 2 readout est. (NCT05800587)
DESCRIPTION:Lurbinectedin\, phase 2\, Small Cell Lung Cancer.\nStudy: Dose 
 Attenuated Chemotherapy in Compromised Patients With Lung Cancer\nEstimate
 d primary completion: 1 August 2028. This is a ClinicalTrials.gov estimate
 \, not a confirmed readout date\, and it can move.\nDrug page: https://ass
 etmemo.bio/drug/lurbinectedin#upcoming-events\nRegistry record: https://cl
 inicaltrials.gov/study/NCT05800587
URL:https://assetmemo.bio/drug/lurbinectedin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07153055-2601@assetmemo.bio
DTSTAMP:20261121T005647Z
DTSTART;VALUE=DATE:20290430
DTEND;VALUE=DATE:20290501
SUMMARY:Lurbinectedin: Phase 1/2 readout est. (NCT07153055)
DESCRIPTION:Lurbinectedin\, phase 1/2\, Small Cell Lung Cancer.\nStudy: Lur
 binectedin With Osimertinib in Transformed Small Cell Lung Cancer\nEstimat
 ed primary completion: April 2029. This is a ClinicalTrials.gov estimate\,
  not a confirmed readout date\, and it can move.\nDrug page: https://asset
 memo.bio/drug/lurbinectedin#upcoming-events\nRegistry record: https://clin
 icaltrials.gov/study/NCT07153055
URL:https://assetmemo.bio/drug/lurbinectedin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07155174-2601@assetmemo.bio
DTSTAMP:20261121T005647Z
DTSTART;VALUE=DATE:20290430
DTEND;VALUE=DATE:20290501
SUMMARY:Lurbinectedin: Phase 2 readout est. (NCT07155174)
DESCRIPTION:Lurbinectedin\, phase 2\, Small Cell Lung Cancer.\nStudy: A Stu
 dy to Evaluate the Optimal Dose\, Adverse Events and Change in Disease Act
 ivity of Intravenous ABBV-706 in Combination With Atezolizumab Versus Stan
 dard of Care as First-Line Treatment in Adult Participants With Previously
  Untreated Extensive Stage Small Cell Lung Cancer\nEstimated primary compl
 etion: April 2029. This is a ClinicalTrials.gov estimate\, not a confirmed
  readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/lu
 rbinectedin#upcoming-events\nRegistry record: https://clinicaltrials.gov/s
 tudy/NCT07155174
URL:https://assetmemo.bio/drug/lurbinectedin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07459634-2601@assetmemo.bio
DTSTAMP:20261121T005647Z
DTSTART;VALUE=DATE:20290804
DTEND;VALUE=DATE:20290805
SUMMARY:Lurbinectedin: Phase 2 readout est. (NCT07459634)
DESCRIPTION:Lurbinectedin\, phase 2\, Small Cell Lung Cancer.\nStudy: A Stu
 dy of Lurbinectedin in Combination With Durvalumab for the Treatment of Pa
 rticipants With ES-SCLC\nEstimated primary completion: 4 August 2029. This
  is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it 
 can move.\nDrug page: https://assetmemo.bio/drug/lurbinectedin#upcoming-ev
 ents\nRegistry record: https://clinicaltrials.gov/study/NCT07459634
URL:https://assetmemo.bio/drug/lurbinectedin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06088290-2601@assetmemo.bio
DTSTAMP:20261121T005647Z
DTSTART;VALUE=DATE:20290830
DTEND;VALUE=DATE:20290831
SUMMARY:Lurbinectedin: Phase 3 readout est. (NCT06088290)
DESCRIPTION:Lurbinectedin\, phase 3.\nStudy: Study of Lurbinectedin in Comb
 ination With Doxorubicin Versus Doxorubicin Alone as First-line Treatment 
 in Participants With Metastatic Leiomyosarcoma (SaLuDo)\nEstimated primary
  completion: 30 August 2029. This is a ClinicalTrials.gov estimate\, not a
  confirmed readout date\, and it can move.\nDrug page: https://assetmemo.b
 io/drug/lurbinectedin#upcoming-events\nRegistry record: https://clinicaltr
 ials.gov/study/NCT06088290
URL:https://assetmemo.bio/drug/lurbinectedin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06801834-2601@assetmemo.bio
DTSTAMP:20261121T005647Z
DTSTART;VALUE=DATE:20291031
DTEND;VALUE=DATE:20291101
SUMMARY:Lurbinectedin: Phase 3 readout est. (NCT06801834)
DESCRIPTION:Lurbinectedin\, phase 3\, Small Cell Lung Cancer.\nStudy: Study
  of Sacituzumab Govitecan Versus Standard of Care in Participants With Pre
 viously Treated Extensive Stage Small Cell Lung Cancer\nEstimated primary 
 completion: October 2029. This is a ClinicalTrials.gov estimate\, not a co
 nfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/
 drug/lurbinectedin#upcoming-events\nRegistry record: https://clinicaltrial
 s.gov/study/NCT06801834
URL:https://assetmemo.bio/drug/lurbinectedin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07141771-2601@assetmemo.bio
DTSTAMP:20261121T005647Z
DTSTART;VALUE=DATE:20300630
DTEND;VALUE=DATE:20300701
SUMMARY:Lurbinectedin: Phase 1/2 readout est. (NCT07141771)
DESCRIPTION:Lurbinectedin\, phase 1/2\, Small Cell Lung Cancer.\nStudy: An 
 Umbrella Study of Recurrent\, Extensive Stage Small Cell Lung Cancer Based
  on Molecular Typing\nEstimated primary completion: 30 June 2030. This is 
 a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can 
 move.\nDrug page: https://assetmemo.bio/drug/lurbinectedin#upcoming-events
 \nRegistry record: https://clinicaltrials.gov/study/NCT07141771
URL:https://assetmemo.bio/drug/lurbinectedin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07328425-2601@assetmemo.bio
DTSTAMP:20261121T005647Z
DTSTART;VALUE=DATE:20301001
DTEND;VALUE=DATE:20301002
SUMMARY:Lurbinectedin: Phase 2 readout est. (NCT07328425)
DESCRIPTION:Lurbinectedin\, phase 2.\nStudy: Clinical Study in Adult and Yo
 ung Adult Patients With Advanced Desmoplastic Small Round Cell Tumor (DSRC
 T) ISG-TULIPS\nEstimated primary completion: 1 October 2030. This is a Cli
 nicalTrials.gov estimate\, not a confirmed readout date\, and it can move.
 \nDrug page: https://assetmemo.bio/drug/lurbinectedin#upcoming-events\nReg
 istry record: https://clinicaltrials.gov/study/NCT07328425
URL:https://assetmemo.bio/drug/lurbinectedin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
